This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sarepta CEO: $125 Million Offering Demand Was Strong

BOSTON ( TheStreet) -- I chatted briefly by phone with Sarepta Therapeutics (SRPT - Get Report) CEO Chris Garabedian following the successful follow-on stock offering that raised $125 million.

Here are some excerpts from our conversation:

On investor demand for the offering:

"We went out with a target of raising $75 million but by the time we were ready to close the book we were more than three times oversubscribed, almost four times... The book was full of top quality institutional investors, many of whom were not going to get the allocation they wanted, so we decided to upsize the offering."

On Sarepta's new shareholder base:

"Previously, we had about 35% institutional investors. With the close of this offering, we're up to 50%, including a lot of long-only accounts and good fundamental life-sciences investors. It's really nice to see the company's shareholder base change.

On the timing of the stock offering:

"It's hard to find the right [financing] window where we don't have disclosure issues... But we had the 62-week eteplirsen data behind us, investor demand was high and you always worry about macro risk so we decided to get [an offering] in before the end of the year. It's nice to enjoy the holidays knowing we have a very healthy balance sheet."

On plans for the FDA meeting to discuss the possibility of filing accelerated approval for eteplirsen:

"We're sticking with our guidance that we will be requesting a meeting with FDA before the end of the year, which puts us squarely on track to have the meeting in the first quarter."

When can investors expect to hear from Sarepta about the outcome of the FDA meeting?

"We won't be saying anything publicly until we get the final minutes from the FDA meeting, which probably means a March-April timeframe. At that point, we'll update investors on whether or not we will be pursuing an accelerated approval [for eteplirsen.]"

On eteplirsen manufacturing and timing of a possible eteplirsen approval filing:

"We need to have difference discussions with FDA about clinical and manufacturing issues. The plan right now is to meet with FDA about CMC [chemistry, manufacturing and controls] in the second quarter... How or when we file will be dictated by the outcome and feedback we get from FDA at both these meetings."
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GILD $88.04 -9.20%
SRPT $14.20 2.90%
AAPL $93.75 -1.10%
FB $117.63 0.77%
GOOG $693.66 0.38%


Chart of I:DJI
DOW 17,776.11 -54.65 -0.31%
S&P 500 2,068.80 -7.01 -0.34%
NASDAQ 4,779.82 -25.4710 -0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs